Continuous positive airway pressure improves nocturnal symptoms but not lung function tests. Gastric suppression treatment in patients with both gastroesophageal reflux disease and nocturnal asthma improved the peak expiratory flow rate. Even though, the asthma symptom can be treated by var-ious medications, targeting to control the inflammatory pro-cesses or direct bronchodilation effect such as various type of beta-2 receptor agonist drugs, there are still remaining asth-matic patients with nocturnal symptom. The Gly16 polymorphism of the beta2-receptor is common in nocturnal asthma. Obstructive sleep apnea may be prevalent in nocturnal asthma. Nocturnal symptoms in asthma are frequently underdiagnosed. After continuous positive airway pressure treatment, there was significant improvement of asthma nighttime symptom scores however, no significant difference in lung functions was observed. However, nocturnal continuous positive airway pressure treatment did improve asthma quality of life. asthma treatment must be sufficient to cover these hours. In conclusion, nocturnal continuous positive airway pressure treatment did not alter airway responsiveness or forced expiratory volume in one second in subjects with stable mild-to-moderate asthma and newly diagnosed obstructive sleep apnoea. Of patients with nocturnal asthma and snoring, 48% had obstructive sleep apnea. Nocturnal asthma, with symptoms like chest tightness, shortness of breath, cough, and wheezing at night. A randomized double-blind study of nocturnal asthma with esomeprazole improved the peak expiratory flow rate in individuals with both nocturnal asthma and gastroesophageal reflux disease. A recent study including 47 individuals with nocturnal and nonnocturnal asthma showed that allele genotype Gly16 was significantly higher in the nocturnal asthma group (72%) compared with the nonnocturnal asthma group (54%). Forty-two percent of patients who completed the study did not declare nocturnal symptoms that were detected by physicians. In a large cross-sectional survey, the prevalence of nocturnal symptoms was 60%. To examine recent advancements of the epidemiology, pathophysiology, and treatment of nocturnal asthma.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |